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Linezolid TherapyqTo the Editor: Jiangsu Province Hospital in Nanjing, China. ThrombocytopeniaTable 1
Comparison of the clinical characteristics of patients with development of thrombo-
cytopenia and thosewithout development of thrombocytopeniawho received intra-
venous linezolid therapy.
Patients with
thrombocytopenia
(n ¼ 24)
Patients without
thrombocytopenia
(n ¼ 26)
p
Age (y) 83  9 80  11 0.344
Sex (n)
Male 17 19 0.861Linezolid is an oxazolidinone antibiotic with a broad spectrum
of activity against Gram-positive organisms including methicillin-
resistant Staphylococcus aureus, also known as MRSA1. However,
linezolid has been associated with hematological adverse effects
such as thrombocytopenia2. At present, there are only a few studies
that have reported this hematological effect in the elderly. In a
retrospective study of the medical charts of elderly patients who
were treated with intravenous linezolid, we analyzed the hemato-
logical properties during treatment and identiﬁed risk factors asso-
ciated with thrombocytopenia.
In total, 50 patients with a mean age of 81 years (range¼ 60e96
years) were included in the study. Linezolid therapy was limited to
those who were infected with resistant Gram-positive bacteria,
especially with renal dysfunction, and those who experienced
treatment failure with vancomycin or teicoplanin. Patients who
showed severe thrombocytopenia (<50  109/L) before linezolid
treatment, bleeding, recent clinically signiﬁcant coagulopathy,
known liver disease, or taking any anticancer drugs during linezolid
treatment were excluded. Patients were treated with linezolid at
600 mg IV BID (q12h) between January 2008 and October 2010 atFig. 1. Mean platelet count in patients with development of thrombocytopenia during
linezolid therapy. Platelet count is expressed as 109/L (n ¼ 18). #p < 0.05, comparison
between PLT count (131  83, d7) vs. PLT count before treatment (210  114, d1);
*p < 0.01, comparison between PLT count (60  30, d14) vs. PLT count before
treatment; **p < 0.01, comparison between PLT count (55  24, d15) vs. PLT count
before treatment; Dp < 0.01 comparison between PLT count 7 days after the end of
therapy (118  62, d21) vs. PLT count (55  24, d15). d ¼ day; PLT ¼ platelet.
q The authors declare that they have no ﬁnancial or non-ﬁnancial conﬂicts of in-
terest related to the subject matter or materials discussed in the article.
http://dx.doi.org/10.1016/j.ijge.2013.10.004
1873-9598/Copyright  2014, Taiwan Society of Geriatric Emergency & Critical Care Mewas deﬁned as a decrease in platelet count of 25% and a ﬁnal
count of <100  109/L.
Thrombocytopenia occurred in 24 patients, indicating the inci-
dence of 48%. The patterns of changes in platelet counts are demon-
strated in Fig. 1 of patients who were treated with linezolid for 14
days.We found that themean platelet count decreased signiﬁcantly
from the 7th day of treatment and decreased to the lowest value 1
day after the end of therapy, whereas it increased to near normal
values 7 days after the end of therapy. In addition, we found that
thrombocytopenia was associated with both the duration of treat-
ment and the baseline platelet count (Table 1), and the baselineFemale 7 7
Length of stay (d) 47  29 51  32 0.658
Baseline ALT (U/L) 44  42 23  14 0.159
Baseline CCr (mL/min) 46  36 60  43 0.290
Baseline HGB (g/L) 104  21 99  16 0.358
Baseline PLT (109/L) 204  118 272  101 0.042
Treatment duration (d) 14  2 12  2 0.005
Baseline LDH (U/L) 289  182 272  168 0.815
ALT ¼ alanine aminotransferase; CCr ¼ creatinine clearance; HGB ¼ hemoglobin;
LDH ¼ lactate dehydrogenase; PLT ¼ platelet.
Table 2
Comparison of the clinical characteristics of patients with severe thrombocytopenia
and those with moderate thrombocytopenia who received intravenous linezolid
therapy.
Patients with severe
thrombocytopenia
(<50  109/L) (n ¼ 8)
Patients with moderate
thrombocytopenia
(50e100 109/L) (n ¼ 16)
p
Age (y) 82  7 83  10 0.903
Length of stay (d) 52  22 44  25 0.478
Baseline ALT (U/L) 48  11 40  39 0.872
Baseline CCr (mL/min) 49  36 47  39 0.915
Baseline HGB (g/L) 110  17 97  24 0.089
Baseline PLT (109/L) 144  66 238  111 0.024
Treatment duration (d) 15  3 14  2 0.638
Baseline LDH (U/L) 283  175 292  194 0.927
ALT ¼ alanine aminotransferase; CCr ¼ creatinine clearance; HGB ¼ hemoglobin;
LDH ¼ lactate dehydrogenase; PLT ¼ platelet.
dicine. Published by Elsevier Taiwan LLC. All rights reserved.
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thrombocytopenia (Table 2).
It was reported that platelet count might be associated with
metabolic syndrome3 and bone marrow suppression in elderly pa-
tients. The mechanisms underlying linezolid-induced hematologi-
cal toxicity remain to be clariﬁed.References
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